Corona Virus Therapeutics Clinical Trial Results Begin May 24 at 19:15
As research institutes and pharmaceutical companies around the world rush to study new coronavirus drugs, clinical trials are beginning to show the effectiveness of potential drugs, and attention is focused on whether this will lead to the establishment of a treatment.
A clinical trial is underway over the new coronavirus, which is not being treated as a therapeutic effect on drugs developed to treat other diseases.
Of these, Remdesivir, which was being developed by The Gilead Sciences, an American pharmaceutical company, was developed as a treatment for Ebola, and this month, based on some results of clinical trials, an emergency permit was issued in the United States.
The early stages of clinical trials by the National Institutes of Health, published on 22 Nde, showed that the time to reduce the time it takes for patients to be discharged from the hospital has been sentenced.
On the other hand, “hydroxychloroquine”, which is widely used as a therapeutic agent for malaria, was widely used around the world, but it has been reported that the results of a large-scale patient analysis published on 22 nd showed no effect.
In addition, American pharmaceutical companies are developing antibodies made from viral antibodies and immunoglobulin formulations made from plasma in recovered patients, but clinical trials are expected to begin this summer.
In the United States and other countries, the number of people infected is becoming more gradual, but it is urgent to verify the effects of drugs in case the number of infected people begins to increase again.
Research on the Corona Virus drug
“Remdesivir”, developed by an American pharmaceutical company, has been approved for emergency use in the United States, and has been approved in Japan using a special approval system. However, because information about safety such as side effects is still limited, it is supposed to be used carefully only for severely ill patients. In addition, there are many studies on medicines and treatments aimed at treating the new coronavirus in Japan and overseas.
Of these, Abigan, a new influenza drug developed by a Japanese pharmaceutical company, is expected to prevent the growth of the virus by preventing the growth of rna swells in genes, and is expected to be effective in the same mechanism for the new coronavirus.
Although research has been reported to have been observed in China and elsewhere, there have been no results of clinical research by companies in Japan or clinical research involving more than 40 medical institutions nationwide.
The government has indicated that it will shorten the procedures and proceed with the review with the aim of approving this month, but there are some calls for careful consideration of the effectiveness and safety, and the results of corporate clinical trials and clinical research are attracting attention in the future.
Orvesco, a treatment for asthma, is a drug that the National Institute of Infectious Diseases has found to be effective against the new coronavirus, and is expected to prevent severe illness by using it in early patients.
The results of observational research on more than 300 people are expected to be finalized soon, and clinical research is also underway at the National Center for International Medical Research.
The common name “Fusan”, which a research group at the University of Tokyo has found the potential to suppress the growth of the new coronavirus, and the common name “Nafamostat” have long been used in Japan as a treatment for diseases capable of thrombus in the body and blood clots.
There have been reports that the new coronavirus is more likely to cause blood clots and blood clots to become severe, and the group is conducting clinical studies that may prevent the growth of the virus and prevent blood clots by using “husan”.
In addition, “Ibermectin”, which was developed based on materials discovered by Prof. Satoshi Omura of Kitasato University, who won the Nobel Prize in Medicine and Physiology in 2015, is also expected to be effective.
It is originally a special effect of parasitic infections, but there have been reports that american universities have been given this drug to patients with a new type of coronavirus to reduce their mortality rate, and Kitasato University is going to conduct clinical research in the future.
Rheumatism drugs, Actemura
Actemura, a therapeutic agent for rheumatoid arthritis developed based on the results of Japanese researchers, is expected to have the effect of suppressing the runaway immunity caused by the new coronavirus.
In the new coronavirus, “cytokine storm” that the immune system runs out in some patients occurs, and it is said that it becomes severe, and “Actemura” may lead to the improvement of the symptom.
In addition to announcing that the pharmaceutical company that developed the drug company will conduct clinical trials in Japan to confirm the effectiveness, clinical trials are underway overseas.
In addition, “Caletra” to suppress the onset of AIDS, and “hydroxychloroquine”, a therapeutic agent such as malaria, have been studied, but enough effects have not been confirmed so far.
Expected to treat other diseases
The new coronavirus is initially a symptom of so-called “colds”, such as fever and cough, and it is said that people of about eight percent can recover as they are without any special treatment.
However, if pneumonia becomes severe, treatment is necessary in a ventilator or intensive care unit, and some people die, so it is necessary to develop a treatment to prevent it from becoming severe. As a result, the development of new coronavirus drugs is underway at a rapid pace around the world.
Recently, attention has been focused on not developing new drugs from the beginning, but rather a way to find the effects of the new coronavirus from drugs that have been developed as therapeutic agents for other diseases or have already been put to practical use.
These drugs are expected to be used more quickly than in developing new drugs, although it is necessary to confirm the effects and safety of the new coronavirus against the new coronavirus, because it has already been used by people and information on side effects.
Experts ” Prepare by the second wave “
Tsuneo Morishima, a visiting professor at Aichi Medical University who is well versed in the treatment of infectious diseases, commented on the development of therapeutic agents for the new coronavirus, saying, “It is absolutely necessary to confirm the effects in the form of appropriate clinical research in order to put them to practical use as drugs. I think Abigan will get the fastest results in the drug that is now a candidate. In addition, Orvesco is expected to produce results after June, and research is progressing with a sense of speed, such as Husan and Actemura. It is said that the second wave of infection and the third wave will come, so we need to be well prepared by then.”
On the other hand, Visiting Morishima said, “All the therapeutic agents currently being studied are looking for existing drugs, and there are certain limitations because they are not drugs developed specifically for the new coronavirus. It’s important to understand the pros and cons and use them.”